SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy.

Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California; University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota; Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York; Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California; Department of Radiology, University of Washington, Seattle, Washington; Department of Radiology, Brigham and Women’s Hospital, and Department of Imaging, Dana-Farber Cancer Institute, Boston, Massachusetts; Banner M.D. Anderson Cancer Center, Phoenix, Arizona; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Molecular Imaging and Therapeutics, Department of Radiology, Weill Cornell Medicine, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New York; Mayo Clinic, Rochester, Minnesota; and Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York